Literature DB >> 6289026

Naltrexone, opiate addiction, and endorphins.

M S Gold, C A Dackis, A L Pottash, H H Sternbach, W J Annitto, D Martin, M P Dackis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6289026     DOI： 10.1002/med.2610020302

Source DB:  PubMed          Journal:  Med Res Rev        ISSN： 0198-6325            Impact factor:   12.944


× No keyword cloud information.
  12 in total

1.  75 years of opioid research: the exciting but vain quest for the Holy Grail.

Authors:  Alistair D Corbett; Graeme Henderson; Alexander T McKnight; Stewart J Paterson
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

2.  14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.

Authors:  Guo Li; Lindsey C K Aschenbach; Hengjun He; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-12-29       Impact factor: 2.823

3.  Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?

Authors:  Kenneth Blum; Thomas J H Chen; John Bailey; Abdalla Bowirrat; John Femino; Amanda L C Chen; Thomas Simpatico; Siobhan Morse; John Giordano; Uma Damle; Mallory Kerner; Eric R Braverman; Frank Fornari; B William Downs; Cynthia Rector; Debmayla Barh; Marlene Oscar-Berman
Journal:  Mol Neurobiol       Date:  2011-09-24       Impact factor: 5.590

4.  Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.

Authors:  Saheem A Zaidi; Christopher K Arnatt; Hengjun He; Dana E Selley; Philip D Mosier; Glen E Kellogg; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2013-09-04       Impact factor: 3.641

5.  Affinity profiles of novel delta-receptor selective benzofuran derivatives of non-peptide opioids.

Authors:  M Spetea; S T Nevin; S Hosztafi; A Z Rónai; G Tóth; A Borsodi
Journal:  Neurochem Res       Date:  1998-09       Impact factor: 3.996

6.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

7.  Naltrexone effects on pituitary neurointermediate lobe and median eminence.

Authors:  L C Saland; E Reyes; E Ortiz
Journal:  Neurochem Res       Date:  1984-02       Impact factor: 3.996

Review 8.  Opioids and behavior: genetic aspects.

Authors:  H R Frischknecht; B Siegfried; P G Waser
Journal:  Experientia       Date:  1988-06-15

Review 9.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

10.  Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

Authors:  Guo Li; Lindsey C Aschenbach; Jianyang Chen; Michael P Cassidy; David L Stevens; Bichoy H Gabra; Dana E Selley; William L Dewey; Richard B Westkaemper; Yan Zhang
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.